Related content

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant - reagents for tumor immunology

By Dazzi F.   Szydlo R.M.   Goldman J.M.  

Experimental Hematology, Vol. 27, Iss. 10, 1999-10 ,pp. : 1477-1486

Elsevier

Access to resources Recommend Favorite

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3⁺ and CD4⁺ lymphocytes

By Vela-Ojeda J.   García-Ruiz Esparza M.   Reyes-Maldonado E.   Jiménez-Zamudio L.   Moreno-Lafont M.   García-Latorre E.   Ramírez-Sanjuan E.   Montiel-Cervantes L.   Tripp-Villanueva F.   García-León L.   Ayala-Sánchez M.   Rosas-Cabral A.   Aviña-Zubieta J.   Galindo-Rodríguez G.   Vadillo-Buenfil M.   Salazar-Exaire D.  

Annals of Hematology, Vol. 83, Iss. 5, 2004-05 ,pp. : 295-301

Springer Publishing Company

Access to resources Recommend Favorite

Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis - A sequential study in 42 patients

By Hernandez-Boluda J.-C.   Cervantes F.   Colomer D.   Vela M.-C.   Costa D.   Paz M.-F.   Esteller M.   Montserrat E.  

Experimental Hematology, Vol. 31, Iss. 3, 2003-03 ,pp. : 204-210

Elsevier

Access to resources Recommend Favorite

Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling—evaluation of risks and benefits

By Koh L.  

Annals of Hematology, Vol. 83, Iss. 5, 2004-05 ,pp. : 286-294

Springer Publishing Company

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite